ASCO submitted testimony to the U.S. House and Senate Appropriations Committees urging them to increase funding for the National Institutes of Health, National Cancer Institute, and Food and Drug Administration.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
ASCO joined the Alliance for Childhood Cancer on Capitol Hill for the 8th Annual Childhood Cancer Action Day, where advocates met directly with Members of Congress and their staff about cancer policy priorities related to pediatric cancer.
During the Action Day, advocates urged Members of Congress to:
Three completed cohorts reporting findings in non-small cell lung cancer, breast, and metastatic colorectal cancer from the American Society of Clinical Oncology, Inc.’s (ASCO®) Targeted Agent and Profiling Utilization Registry (TAPUR™) Study were presented in poster sessions during the American Association for Cancer Research (AACR) Annual Meeting 2019. In addition, all seven pharmaceutical companies currently participating in the TAPUR Study have recently renewed their commitment to support it and provide study drugs at no cost for an additional one to three years.
Today, ASCO is kicking off its Fiscal Year (FY) 2020 advocacy campaign in support of increased funding for federal cancer research. The launch of this year’s advocacy effort comes as Congress is beginning its work to craft FY 2020 appropriations bills. As part of the campaign, ASCO is urging Congress to provide $41.6 billion to the National Institutes of Health (NIH) – a $2.5 billion increase from FY 2019 – and $6.5 billion to the National Cancer Institute (NCI).
ASCO joined hundreds of other patient groups, scientific societies, and research and health care institutions in urging members of Congress to increase federal funding for cancer research and prevention in the Fiscal Year (FY) 2020 funding bill.
The Workshop on Development of Tissue-Agnostic, Biomarker-Based Indications, cohosted by ASCO, the Food and Drug Administration (FDA), and Friends of Cancer Research, is now open for registration. The April 26 full-day event will take place at the FDA White Oak Campus in Silver Spring, Maryland.
Two of the world’s leading cancer organizations have released national strategies for meeting the needs of the growing population of cancer survivors in the United States while addressing provider shortages and rising costs. ASCO and the American Cancer Society convened a summit in January of 2018 focused on developing and implementing care that addresses these issues by treating patients in personalized follow-up care pathways depending on the type and level of resources needed for their long-term care. The strategies from that summit were published on March 8, in CA: A Cancer Journal for Clinicians.
On April 10, ASCO will convene some of the nation’s top physicians, advocates and rural health experts for a discussion on the challenges facing Americans living with cancer in rural areas and promising opportunities to improve outcomes.
"We strongly oppose the White House budget proposal for Fiscal Year (FY) 2020, which would stall our nation’s progress against cancer and impede access to needed care for the millions of Americans dealing with cancer. The proposal would make drastic, unprecedented cuts to the U.S. Department of Health and Human Services—which houses the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Centers for Medicare & Medicaid Services (CMS)."
On March 11, the Journal of Oncology Practice (JOP) published, “State of Cancer Care in America: Reflections on an Inaugural Year,” which highlights key takeaways from the 2018 State of Cancer Care in America series. The JOP series, which examines trends and critical challenges in the delivery of cancer care, used the findings from the 2017 ASCO Practice Census (the Census), a survey of U.S. oncology practices, as its starting point to identify the most pressing issues in cancer care. The series includes articles on trending topics on cancer care, along with commentaries from payers, oncologists, and regulators.
ASCO Chief Medical Officer Dr. Richard Schilsky recently joined ASCO CEO Dr. Clifford A. Hudis to discuss the 2019 Clinical Cancer Advances (CCA) report on the ASCO in Action Podcast. The CCA report identifies the most important clinical research advances from the past year across the full trajectory of cancer care, ranging from prevention and screening to treatment and survivorship.
On February 20 ASCO announced that it is seeking applications for research grants for projects that use data from CancerLinQ Discovery®, an offering of ASCO’s CancerLinQ® initiative, as a source.
Urge Congress to support the CLINICAL TREATMENT Act, which would guarantee coverage of the routine care costs of clinical trial participation for Medicaid enrollees with a life-threatening condition.
On February 12, 2019, ASCO leadership and members of the society’s Government Relations Committee met with representatives from key federal agencies, advisory groups, and other stakeholder organizations to discuss top cancer policy priorities. The meetings focused on access to clinical trials, drug pricing, step therapy, drug shortages, Medicaid waivers and other issues affecting people with cancer.